A Randomized, Phase 1, Double-Blind, Placebo-Controlled, First-in-Human, Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of GC021109 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2015
Price : $35 *
At a glance
- Drugs GC 021109 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors GliaCure
- 14 Dec 2015 According to a GliaCure media release, the company reported pooled clinical results from this and other trial (249754) for the treatment of Alzheimer's disease.
- 17 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Sep 2014 New trial record